Filing Details

Accession Number:
0000905148-20-001037
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-22 17:21:21
Reporting Period:
2020-09-18
Accepted Time:
2020-09-22 17:21:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1634379 Metacrine Inc. MTCR () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1278411 S Corey Goodman 1700 Owens Street
Suite 595
San Francisco CA 94158
No No No No
1504130 Venbio Global Strategic Fund, L.p. 1700 Owens Street, Suite 595
San Francisco CA 94158
No No No No
1770834 Venbio Global Strategic Gp, L.p. 1700 Owens Street, Suite 595
San Francisco CA 94158
No No No No
1770835 Venbio Global Strategic Gp, Ltd. 1700 Owens Street, Suite 595
San Francisco CA 94158
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-09-18 230,000 $13.00 230,000 No 4 P Direct
Common Stock Acquisiton 2020-09-18 2,829,123 $0.00 3,059,123 No 4 C Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 C Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Disposition 2020-09-18 1,960,784 $0.00 1,960,784 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2020-09-18 472,250 $0.00 472,250 $0.00
Common Stock Series C Convertible Preferred Stock Disposition 2020-09-18 396,089 $0.00 396,089 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
  2. The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.